Search results for abx831355

Risankizumab, Abbexa, abx831355

Risankizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis. Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.